| 18.665 0.185 (1%) | 10-28 15:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.42 | 1-year : | 26.86 |
| Resists | First : | 20.91 | Second : | 23 |
| Pivot price | 18.87  |
|||
| Supports | First : | 17.53 | Second : | 14.58 |
| MAs | MA(5) : | 18.55 |
MA(20) : | 19.24 |
| MA(100) : | 16.77 |
MA(250) : | 15.34 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 22.8 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 23 | Low : | 8.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ETON ] has closed above bottom band by 42.5%. Bollinger Bands are 12.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.75 - 18.84 | 18.84 - 18.94 |
| Low: | 17.97 - 18.07 | 18.07 - 18.17 |
| Close: | 18.33 - 18.48 | 18.48 - 18.63 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Tue, 28 Oct 2025
Institutional investors own a significant stake of 44% in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Yahoo Finance
Tue, 28 Oct 2025
Is Eton Pharmaceuticals Inc. a candidate for recovery play - 2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
Tue, 28 Oct 2025
Is Eton Pharmaceuticals Inc. a candidate for recovery play - Earnings Recap Summary & Consistent Income Trade Ideas - newser.com
Tue, 28 Oct 2025
Sector ETF performance correlation with Eton Pharmaceuticals Inc. - Earnings Recap Summary & Daily Stock Momentum Reports - newser.com
Tue, 28 Oct 2025
Is a relief rally coming for Eton Pharmaceuticals Inc. holders - Earnings Miss & High Conviction Investment Ideas - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 62.4 (%) |
| Shares Short | 3,020 (K) |
| Shares Short P.Month | 3,650 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.88 |
| Profit Margin | -7.1 % |
| Operating Margin | -1.5 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | -22.1 % |
| Qtrly Rev. Growth | 108.5 % |
| Gross Profit (p.s.) | 1.37 |
| Sales Per Share | 2.16 |
| EBITDA (p.s.) | 0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 12 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -124.27 |
| PEG Ratio | 0 |
| Price to Book value | 20.94 |
| Price to Sales | 8.59 |
| Price to Cash Flow | 40.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|